Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

2.

Freezing of gait as a complication of multiple sclerosis.

Fietzek UM, Paulig M, Fischer P, Ceballos-Baumann AO, Neuhaus O.

Parkinsonism Relat Disord. 2018 Sep;54:121-122. doi: 10.1016/j.parkreldis.2018.04.012. Epub 2018 Apr 14. No abstract available.

PMID:
29680309
3.

Essential thrombocytosis 40 years after splenectomy.

Neuhaus O, Käfer G.

BMJ Case Rep. 2018 Mar 30;2018. pii: bcr-2017-223959. doi: 10.1136/bcr-2017-223959. No abstract available.

PMID:
29602892
4.

Subacute combined degeneration of the spinal cord in vitamin B12 and copper deficiency.

Schimana R, Ober H, Neuhaus O.

BMJ Case Rep. 2017 Dec 20;2017. pii: bcr-2017-222446. doi: 10.1136/bcr-2017-222446. No abstract available.

PMID:
29269366
5.

Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Sasidhar MV, Chevooru SK, Eickelberg O, Hartung HP, Neuhaus O.

PLoS One. 2017 Dec 18;12(12):e0189701. doi: 10.1371/journal.pone.0189701. eCollection 2017.

6.

Teaching NeuroImages: Three complications of small-cell lung cancer involving the brain.

Neuhaus O, Käfer G.

Neurology. 2017 Jul 25;89(4):e40. doi: 10.1212/WNL.0000000000004150. No abstract available.

PMID:
28739671
7.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

8.

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.

Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke KD, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Rückriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K; NEMOS (Neuromyelitis Optica Study Group).

Mult Scler. 2017 Jul;23(8):1092-1103. doi: 10.1177/1352458516671203. Epub 2016 Oct 6.

PMID:
27758954
9.

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group.

Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554. Epub 2015 Nov 26.

PMID:
26537743
10.

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zettl U UK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F.

J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14.

11.

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.

CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. Review.

12.

[Cytokines and their role in pathogenesis of diabetic retinopathy].

Tret'iak EB, Syroedova ON, Neuhaus O, Andreeva AV, Antsiferov MB, Mkrtumian AM, Suchkov SV.

Vestn Oftalmol. 2010 Nov-Dec;126(6):53-7. Review. Russian.

PMID:
21395004
13.

Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.

Cepok S, Schreiber H, Hoffmann S, Zhou D, Neuhaus O, von Geldern G, Hochgesand S, Nessler S, Rothhammer V, Lang M, Hartung HP, Hemmer B.

Arch Neurol. 2009 Oct;66(10):1216-23. doi: 10.1001/archneurol.2009.138. Epub 2009 Aug 10.

PMID:
19667211
14.

Glatiramer acetate: evidence for a dual mechanism of action.

Blanchette F, Neuhaus O.

J Neurol. 2008 Mar;255 Suppl 1:26-36. doi: 10.1007/s00415-008-1005-5. Review.

PMID:
18317674
15.

Spotlight on statins.

Weber MS, Stuve O, Neuhaus O, Hartung HP, Zamvil SS.

Int MS J. 2007 Sep;14(3):93-7. Review.

PMID:
18028833
16.

Immunosuppressive agents in multiple sclerosis.

Neuhaus O, Kieseier BC, Hartung HP.

Neurotherapeutics. 2007 Oct;4(4):654-60. Review.

PMID:
17920546
17.

Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS.

Habisch HJ, Schwalenstöcker B, Danzeisen R, Neuhaus O, Hartung HP, Ludolph A.

Exp Neurol. 2007 Aug;206(2):288-95. Epub 2007 May 18.

PMID:
17597611
18.

Impact of HMG-CoA reductase inhibition on brain pathology.

Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, Nitsch R, Hartung HP.

Trends Pharmacol Sci. 2007 Jul;28(7):342-9. Epub 2007 Jun 15. Review.

PMID:
17573124
19.

Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.

Neuhaus O, Hartung HP.

Expert Rev Neurother. 2007 May;7(5):547-56. Review.

PMID:
17492904
20.

Postinfectious immunodeficiency and autoimmunity: pathogenic and clinical values and implications.

Khitrov AN, Shogenov ZS, Tretyak EB, Ischenko AI, Matsuura E, Neuhaus O, Paltsev MA, Suchkov SV.

Expert Rev Clin Immunol. 2007 May;3(3):323-31. doi: 10.1586/1744666X.3.3.323.

PMID:
20477676
21.

Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.

Neuhaus O, Kieseier BC, Hartung HP.

J Neurol Sci. 2007 Aug 15;259(1-2):27-37. Epub 2007 Mar 27. Review.

PMID:
17391705
22.

Cerebellar infarction after gamma knife radiosurgery of a vestibular schwannoma.

Neuhaus O, Saleh A, van Oosterhout A, Siebler M.

Neurology. 2007 Feb 20;68(8):590. No abstract available.

PMID:
17310028
23.

New diagnostic options in tuberculous meningitis?

Neuhaus O, Manda VS, Scarpatetti M, Höfler G, Hartung HP, Archelos JJ.

Int J Tuberc Lung Dis. 2006 Aug;10(8):944. No abstract available.

PMID:
16898384
24.

Statins in the treatment of central nervous system autoimmune disease.

Weber MS, Youssef S, Dunn SE, Prod'homme T, Neuhaus O, Stuve O, Greenwood J, Steinman L, Zamvil SS.

J Neuroimmunol. 2006 Sep;178(1-2):140-8. Epub 2006 Jul 24. Review.

PMID:
16860400
25.

Mitoxantrone in multiple sclerosis.

Neuhaus O, Kieseier BC, Hartung HP.

Adv Neurol. 2006;98:293-302. Review. No abstract available.

PMID:
16400840
26.

Acute disseminated encephalomyelitis: an update.

Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, Kieseier BC, Stüve O.

Arch Neurol. 2005 Nov;62(11):1673-80. Review.

PMID:
16286539
27.

Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.

Neuhaus O, Stüve O, Zamvil SS, Hartung HP.

CNS Drugs. 2005;19(10):833-41.

PMID:
16185093
28.

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.

Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stüve O, Hartung HP.

J Neuroimmunol. 2005 Nov;168(1-2):128-37.

PMID:
16171875
29.

Therapeutic role of mitoxantrone in multiple sclerosis.

Neuhaus O, Kieseier BC, Hartung HP.

Pharmacol Ther. 2006 Jan;109(1-2):198-209. Epub 2005 Aug 10. Review.

PMID:
16095713
30.

Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires.

Kawakami N, Odoardi F, Ziemssen T, Bradl M, Ritter T, Neuhaus O, Lassmann H, Wekerle H, Flügel A.

J Immunol. 2005 Jul 1;175(1):69-81.

31.

Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.

Neuhaus O, Stüve O, Archelos JJ, Hartung HP.

J Neurol Sci. 2005 Jun 15;233(1-2):173-7. Epub 2005 Apr 20. Review.

PMID:
15949504
32.

Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.

Ziemssen T, Kümpfel T, Schneider H, Klinkert WE, Neuhaus O, Hohlfeld R.

J Neurol Sci. 2005 Jun 15;233(1-2):109-12.

PMID:
15869765
33.

Mitoxantrone (Novantrone) in multiple sclerosis: new insights.

Neuhaus O, Kieseier BC, Hartung HP.

Expert Rev Neurother. 2004 Jan;4(1):17-26. Review.

PMID:
15853611
34.

Bimanual recoupling by visual cueing in callosal disconnection.

Seitz RJ, Kleiser R, Bütefisch CM, Jörgens S, Neuhaus O, Hartung HP, Wittsack HJ, Sturm V, Hermann MM.

Neurocase. 2004 Aug;10(4):316-25.

PMID:
15788269
35.

Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.

Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H.

J Neuroimmunol. 2005 Feb;159(1-2):155-64. Epub 2004 Dec 28.

PMID:
15652415
36.

[Myopathies under therapy with lipid-lowering agents].

Köller H, Neuhaus O, Schroeter M, Hartung HP.

Nervenarzt. 2005 Feb;76(2):212-7. Review. German.

PMID:
15609055
37.

Mechanisms of mitoxantrone in multiple sclerosis--what is known?

Neuhaus O, Kieseier BC, Hartung HP.

J Neurol Sci. 2004 Aug 15;223(1):25-7. Review.

PMID:
15261556
38.

Are statins a treatment option for multiple sclerosis?

Neuhaus O, Stüve O, Zamvil SS, Hartung HP.

Lancet Neurol. 2004 Jun;3(6):369-71. Review.

PMID:
15157852
39.

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP.

Nervenarzt. 2004 Oct;75(10):1022-6. Review. German.

PMID:
15156287
40.

[Neurological aspects of systemic rheumatological disorders].

Neuhaus O, Hartung HP.

Z Rheumatol. 2004 Apr;63(2):104-12. Review. German.

PMID:
15112088
41.

Statins as potential therapeutic agents in multiple sclerosis.

Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil SS.

Curr Neurol Neurosci Rep. 2004 May;4(3):237-44. Review.

PMID:
15102350
42.

Statins in multiple sclerosis: a new therapeutic option?

Neuhaus O, Archelos JJ, Hartung HP.

Mult Scler. 2003 Oct;9(5):429-30. Review. No abstract available.

PMID:
14582764
43.

[Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].

Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hartung HP.

Nervenarzt. 2003 Aug;74(8):704-7. Review. German.

PMID:
12904873
44.

The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.

Wiendl H, Neuhaus O, Mehling M, Wintterle S, Schreiner B, Mitsdoerffer M, Wienhold W, Weissert R, Wessels J, Hartung HP, Weller M, Tolosa E, Melms A.

J Neuroimmunol. 2003 Jul;140(1-2):177-87.

PMID:
12864987
45.

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.

Neuhaus O, Archelos JJ, Hartung HP.

Trends Pharmacol Sci. 2003 Mar;24(3):131-8. Review.

PMID:
12628358
46.
47.

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ.

Neurology. 2002 Oct 8;59(7):990-7.

PMID:
12370451
48.

[Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies].

Ziemssen T, Neuhaus O, Farina C, Hartung HP, Hohlfeld R.

Nervenarzt. 2002 Apr;73(4):321-31. Review. German.

PMID:
12040979
49.

Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Ziemssen T, Neuhaus O, Hohlfeld R.

Drug Saf. 2001;24(13):979-90.

PMID:
11735654
50.

In search of a disease marker: the cytokine profile of primary progressive multiple sclerosis.

Neuhaus O, Hartung HP.

Mult Scler. 2001 Jun;7(3):143-4. Review. No abstract available.

PMID:
11475435

Supplemental Content

Loading ...
Support Center